DOTMA | CAS#104162-48-3 | cationic lipid

MedKoo Cat#: 555960 | Name: DOTMA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DOTMA is one of the first cationic lipid used for gene transfection. DOTMA is an effective transfection agent in vitro and in vivo. DOTMA carries a positive charge on the surface of liposomes which condenses anionic nucleic acids and promotes efficient interactions between the cell membrane and the liposome. Note: DOTMA is the Z-isomer (or Cis-isomer) chloride salt, which CAS# is 104162-48-3. While DOTMA E-isomer (trans-isomer) chloride salt has CAS#104872-42-6. Some vendors confused each other.

Chemical Structure

DOTMA

CAS#104162-48-3 (Z-isomer chloride)

Theoretical Analysis

MedKoo Cat#: 555960

Name: DOTMA

CAS#: 104162-48-3 (Z-isomer chloride)

Chemical Formula: C42H84ClNO2

Exact Mass: 669.6191

Molecular Weight: 670.59

Elemental Analysis: C, 75.23; H, 12.63; Cl, 5.29; N, 2.09; O, 4.77

Price and Availability

Size	Price	Availability
25mg	USD 150.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 750.00	Ready to ship
500mg	USD 1,550.00	Ready to ship
1g	USD 2,450.00	Ready to ship
2g	USD 4,150.00	Ready to ship
5g	USD 7,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

104162-48-3 (Z-isomer chloride) 122342-03-4 (Z-isomer cation) 104872-42-6 (E-isomer chloride) 717090-94-3 (E-isomer cation)

Synonym

DOTMA; 1,2-di-O-octadecenyl-3-trimethylammonium propane

IUPAC/Chemical Name

N,N,N-trimethyl-2,3-bis(((Z)-octadec-9-en-1-yl)oxy)propan-1-aminium chloride

InChi Key

LDGWQMRUWMSZIU-LQDDAWAPSA-M

InChi Code

InChI=1S/C42H84NO2.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-44-41-42(40-43(3,4)5)45-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,42H,6-19,24-41H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;

SMILES Code

CCCCCCCC/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\CCCCCCCC)C[N+](C)(C)C.[Cl-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A23T06K12

QC Data

View QC data: current batch, Lot#A23T06K12

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

DOTMA, as a tetra-methylated DOTA analogue, is a cationic lipid and can be used as a non-viral vector for gene therapy.

In vitro activity:

In particular, the Ln(3+) chelates of DOTMA exhibit a marked preference for the monocapped twisted square antiprismatic coordination isomer which imparts more rapid water exchange kinetics on the chelates; τ(M)(298) was determined to be 85 ns for GdDOTMA. Reference: Inorg Chem. 2011 Sep 5;50(17):7955-65. https://pubmed.ncbi.nlm.nih.gov/21819052/

In vivo activity:

The present study aimed to evaluate the incorporation of the natural lipid lycopene into niosome formulations based on cationic lipid DOTMA and polysorbate 60 non-ionic surfactant to analyze the potential application of this novel formulation to deliver genetic material into the rat retina. Both subretinal and intravitreal administrations to the rat retina showed that nioplexes were able to transfect efficiently the outer segments of the retina, which offer reasonable hope for the treatment of many inherited retinal diseases by a safe non-viral vector formulation after the less invasive intravitreal administration. Reference: J Control Release. 2017 May 28;254:55-64. https://pubmed.ncbi.nlm.nih.gov/28347807/

	Solvent	mg/mL	mM
Solubility
	DMSO	50.0	0.03

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 670.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gendron F, Grasser M, Le Guennic B. Near-infrared circular dichroism of the ytterbium DOTMA complex: an ab initio investigation. Phys Chem Chem Phys. 2022 Mar 2;24(9):5404-5410. doi: 10.1039/d1cp01675j. PMID: 35170600. 2. Aime S, Botta M, Garda Z, Kucera BE, Tircso G, Young VG, Woods M. Properties, solution state behavior, and crystal structures of chelates of DOTMA. Inorg Chem. 2011 Sep 5;50(17):7955-65. doi: 10.1021/ic2012827. Epub 2011 Aug 5. PMID: 21819052; PMCID: PMC3204394. 3. Kurosaki T, Kanda H, Hashizume J, Sato K, Harasawa H, Nakamura T, Sasaki H, Kodama Y. Delivery of pDNA to the Lung by Lipopolyplexes Using N-Lauroylsarcosine and Effect on the Pulmonary Fibrosis. Pharmaceutics. 2021 Nov 22;13(11):1983. doi: 10.3390/pharmaceutics13111983. PMID: 34834398; PMCID: PMC8625672. 4. Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017 May 28;254:55-64. doi: 10.1016/j.jconrel.2017.03.386. Epub 2017 Mar 24. PMID: 28347807.

In vitro protocol:

In vivo protocol:

1. Kurosaki T, Kanda H, Hashizume J, Sato K, Harasawa H, Nakamura T, Sasaki H, Kodama Y. Delivery of pDNA to the Lung by Lipopolyplexes Using N-Lauroylsarcosine and Effect on the Pulmonary Fibrosis. Pharmaceutics. 2021 Nov 22;13(11):1983. doi: 10.3390/pharmaceutics13111983. PMID: 34834398; PMCID: PMC8625672. 2. Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017 May 28;254:55-64. doi: 10.1016/j.jconrel.2017.03.386. Epub 2017 Mar 24. PMID: 28347807.

1: Gendron F, Grasser M, Le Guennic B. Near-infrared circular dichroism of the ytterbium DOTMA complex: an ab initio investigation. Phys Chem Chem Phys. 2022 Mar 2;24(9):5404-5410. doi: 10.1039/d1cp01675j. PMID: 35170600. 2: Woods M, Payne KM, Valente EJ, Kucera BE, Young VG Jr. Crystal Structures of DOTMA Chelates from Ce3+ to Yb3+ : Evidence for a Continuum of Metal Ion Hydration States. Chemistry. 2019 Jul 25;25(42):9997-10005. doi: 10.1002/chem.201902068. Epub 2019 Jul 3. PMID: 31121070; PMCID: PMC6700027. 3: Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017 May 28;254:55-64. doi: 10.1016/j.jconrel.2017.03.386. Epub 2017 Mar 24. PMID: 28347807. 4: Kumas C, Fernando WS, Zhao P, Regueiro-Figueroa M, Kiefer GE, Martins AF, Platas-Iglesias C, Sherry AD. Unexpected Changes in the Population of Coordination Isomers for the Lanthanide Ion Complexes of DOTMA-Tetraglycinate. Inorg Chem. 2016 Sep 19;55(18):9297-305. doi: 10.1021/acs.inorgchem.6b01390. Epub 2016 Sep 7. PMID: 27603690; PMCID: PMC5221692. 5: Webber BC, Woods M. Structural analysis of isomeric europium(III) chelates of NB-DOTMA. Inorg Chem. 2012 Aug 6;51(15):8576-82. doi: 10.1021/ic3011597. Epub 2012 Jul 18. PMID: 22809081. 6: Aime S, Botta M, Garda Z, Kucera BE, Tircso G, Young VG, Woods M. Properties, solution state behavior, and crystal structures of chelates of DOTMA. Inorg Chem. 2011 Sep 5;50(17):7955-65. doi: 10.1021/ic2012827. Epub 2011 Aug 5. PMID: 21819052; PMCID: PMC3204394. 7: Matsumoto M, Kishikawa R, Kurosaki T, Nakagawa H, Ichikawa N, Hamamoto T, To H, Kitahara T, Sasaki H. Hybrid vector including polyethylenimine and cationic lipid, DOTMA, for gene delivery. Int J Pharm. 2008 Nov 3;363(1-2):58-65. doi: 10.1016/j.ijpharm.2008.07.010. Epub 2008 Jul 18. PMID: 18687391. 8: Gaucheron J, Santaella C, Vierling P. Transfection with fluorinated lipoplexes based on fluorinated analogues of DOTMA, DMRIE and DPPES. Biochim Biophys Acta. 2002 Aug 31;1564(2):349-58. doi: 10.1016/s0005-2736(02)00469-8. PMID: 12175917. 9: Ren T, Song YK, Zhang G, Liu D. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther. 2000 May;7(9):764-8. doi: 10.1038/sj.gt.3301153. PMID: 10822303. 10: Wollenberg B, Kastenbauer, Mundl H, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Löhrs, Naujoks K, Rollston R. Gene therapy --phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther. 1999 Jan 1;10(1):141-7. doi: 10.1089/10430349950019273. PMID: 10022539. 11: Konopka K, Davis BR, Düzgüneş N. HIV-1 infection of a non-CD4-expressing variant of HUT-78 cells: lack of inhibition by Leu3A antibodies and enhancement by cationic DOTMA liposomes. Adv Exp Med Biol. 1991;300:97-110. doi: 10.1007/978-1-4684-5976-0_7. PMID: 1781348.